BioNexus Gene Lab Corp Common stock (BGLC) stock news · rev $7.4M
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
This BGLC news page leads with what BioNexus Gene Lab Corp Common stock filed — not a scraped headline mill.
No cached 8-K sentence for BGLC yet. We will not pad this page with generic market recap.
Latest reported BGLC revenue for 2025-12-31 was $7.4M. Net income was -$3.0M. Revenue was down 21.9% from 2024-12-31 to 2025-12-31. BGLC currently screens at market cap $6.1M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the BGLC stock page; for the tape open the quote page.
BGLC stock news FAQ
What are BGLC's latest revenue and net income?
Latest cached BioNexus Gene Lab Corp Common stock (BGLC) revenue for Dec 31, 2025 was $7.4M. Net income was -$3.0M. Statements: https://lician.com/financials/bglc
How did BGLC revenue change from the prior cached period?
Cached BioNexus Gene Lab Corp Common stock (BGLC) revenue was down 21.9% from $9.5M (Dec 31, 2024) to $7.4M (Dec 31, 2025). Statements: https://lician.com/financials/bglc
What is BGLC's market cap?
BioNexus Gene Lab Corp Common stock (BGLC) market cap is $6.1M on the latest cached fundamentals snapshot.
What kind of company is BGLC?
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Where is BGLC stock news listed?
Cached stock news for BioNexus Gene Lab Corp Common stock (BGLC) is listed at https://lician.com/news/bglc. Filings: https://lician.com/sec/bglc
Not investment advice.